Net Profit/3 604.5 340.6 (263.8) (43.6%) /1 Including other income and share of profit from investments in associates and JVs /2 Gross profit including share of profit from investments in associates and

- Translation- June 11, 2019 Subject: Notification the Acquisition of share of BS Myco Biotech Company Limited. (Additional Information Memorandum Concerning the Acquisition of Assets) To: Director and Manager

ter 2 Quar ter 1-2 Profit Attributable to Owner of the Parent - Previously Reported 2,200.99 3,559.43 Finance Costs (Increase) / Decrease (114.61) (297.48) Share of Profit of Associates and Joint

future as the price of land tends to rise. Nevertheless, the land is large and requires a lot of capital to trade, the Company would probably require a longer period of time as well as greater financial

) % December , December , Assets . . . . % Liabilities . . . . % Shareholders' equity . . . . % Issued and fully paid-up common share (Million Share) . . . . % Par (Baht) . . . . % 4.1 Assets Overall asset as at

were back on track with 44.5% growth YoY and 3.4% growth QoQ. - In Q1’19, the Company maintained its leadership position with total market share of 31.1% in Brain and Body Boost (“BBB”) products which

executionn !&% %,"O*)()* route trade 6 +".%()* criteria )#$\! .'+!C#[/+P*M$ \% " ' (#"O*! ̀* !!"'% #()* business structure ')'#+"'$".'O,"f+ "%"$(#S#$+]bML")'#+"O.'* L P. trading venues

. Share of profit (loss) from investment in associated company For Quarter 2 of the year 2020, share of profit from investment in associated company was 9.19 million baht compare to 4.92 million bath last

68.6% Gross Profit 813 396 417 105.3% Gross Profit Margin (%) 11.1% 9.3% 1.8% SG&A Expenses 456 310 146 46.9% EBIT before share of profit (loss) from Investment in Associates and Joint Venture 608 275

(Translation) — 1 — (Translation) No. 10000000/ 152 /61 20 June 2018 Subject: Resolutions passed by the Board of Directors Meeting regarding the share acquisition, the tender offer for the entire